Skip to content

Main Navigation

Sonoma Logo White Trans
  • Careers
  • Partnerships
  • Investors
  • Contact
  • Search
  • Our Company
    • About Us
    • Founding Story
    • Our Values In Action
    • Who We Are
  • Our Approach
    • Approach Overview
    • The Autoimmune Problem
    • Our Concept
    • Our Science
    • Manufacturing
    • Publications
  • Platform & Pipeline
    • Platform
    • Pipeline
  • Our Focus
  • Clinical Trials
  • News
    • Press Releases
    • In the News

Publications

Next-generation regulatory T cell therapy

Array
•

Therapeutic use of regulatory T cells for graft-versus-host disease

Array
•

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier

Array
•

Posts navigation

  • «
  • 1
  • 2
Sonoma Logo White Inversion
  • Our Company
    • Founding Story
    • Our Values In Action
    • People & Culture
    • Who We Are
    • Our Focus
    • Clinical Trials
  • Platform & Pipeline
    • Platform
    • Pipeline
  • Our Approach
    • The Autoimmune Problem
    • Our Concept
    • Our Science
    • Manufacturing
    • Publications
  • Careers
  • Partnerships
  • Investors
  • News
  • Contact

© 2025 Sonoma Biotherapeutics.

LinkedIn Twitter
  • Privacy Policy
  • Terms of Use

Fred Lab 1x1

Congratulations to Dr. Fred Ramsdell on receiving the 2025 Nobel Prize for his pioneering work in immunotherapy and breakthrough insights into the role of regulatory T cells (Tregs).

SonomaBio is proud to have Dr. Fred Ramsdell as our former Chief Scientific Officer and current advisor. His pioneering work—alongside the seminal contributions of Dr. Alexander Rudensky and others—has been instrumental in shaping our approach to Treg cell therapies.

These foundational discoveries continue to inspire our mission to transform immunotherapy and deliver breakthrough treatments for the most challenging autoimmune diseases.

Read The Press Release